Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More

Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More
In a landmark study that promises to redefine the landscape of musculoskeletal medicine, researchers at the Institute of Science Tokyo…
Read More
MSD (Merck & Co) has achieved a significant milestone in the fight against Human Immunodeficiency Virus (HIV) with the U.S.…
Read More
The realm of neural interfaces, critical for understanding and treating a myriad of neurological conditions, has long grappled with a…
Read More
The treatment paradigm for locally advanced head and neck squamous cell carcinoma (LA HNSCC) is undergoing a significant transformation, driven…
Read More
Researchers at Michigan State University (MSU) have identified a critical molecular "switch" that triggers a massive surge in sperm energy…
Read More
Acute Myelogenous Leukemia (AML) has long remained one of the most formidable challenges in oncology, characterized by its rapid progression…
Read More
Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech, granting the Chinese biopharmaceutical company the rights…
Read More
Researchers at Johns Hopkins Medicine have announced that a newly funded study by the National Institutes of Health (NIH) is…
Read More
The intricate balance of the human skeletal system relies on a continuous cycle of renewal known as bone remodeling, a…
Read More